Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

naut

Common Stock

Last Annual Value

13.00K

3-Year CAGR

3%

5-Year CAGR

67%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Common Stock

NAUT · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
13.00K
0.0%1.6%N/A 
21.00K
44.2%39.3%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
7.00K
20.5%-86.2%N/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
20.00K
26.0%14.9%N/A
28.00K
1.2%1.5%-9.3%
3.00K
14.5%24.6%N/A
64.65K
30.2%19.7%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
353.00K
-55.3%-32.8%-8.7%
90.00K
41.2%32.5%N/A
91.88K
79.2%41.9%N/A
59.34K
105.9%67.3%15.1%
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.58, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.58